Trident Texofab Reports Turnaround Profitability in Q1 FY27

Net Profit: ₹0.52 crore (₹52.18 lakh) in Q1 FY27; Loss of ₹2.01 crore in Q4 FY26
Revenue: ₹26.14 crore in Q1 FY27; ₹33.57 crore in Q4 FY26

Reader Takeaway: Return to profit is a positive sign, but falling revenue and auditor resignation require attention.

What just happened

Trident Texofab Limited has announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a net profit of ₹0.52 crore (₹52.18 lakh) for the quarter. This marks a significant improvement from the net loss of ₹2.01 crore (₹200.94 lakh) recorded in the previous quarter (Q4 FY26). The earnings per share (EPS) for the quarter stood at ₹0.35.

Revenue from operations during Q1 FY27 was ₹26.14 crore (₹2614.26 lakh), which is lower than the ₹33.57 crore (₹3357.02 lakh) reported in the preceding quarter. Total income for the quarter was ₹26.33 crore (₹2632.79 lakh).

Why this matters

The sequential return to profitability is a key positive development for Trident Texofab shareholders. It indicates a potential operational recovery. However, the decrease in revenue needs to be monitored to understand if this is a temporary trend or a cause for concern.

The company also disclosed the resignation of its statutory auditor, M/s. Shah Kailash & Associates LLP, effective August 10, 2026. The auditor cited increasing professional commitments and workload. The board has appointed M/s. Prit Agrawal & Co. as the internal auditor for FY27.

Additionally, the board approved the cancellation of 9,11,479 warrants and forfeiture of 25% of the amounts received against them due to the expiry of the 18-month conversion period.

The backstory

Trident Texofab operates in the textile sector, manufacturing cotton yarn and fabric. The company has historically faced periods of both profitability and losses, typical for the cyclical nature of the textile industry. Fluctuations in raw material costs, demand, and competition are common factors affecting performance.

What changes now

With the return to profitability, the company aims to build on this momentum. Investors will be looking for sustained profits and revenue growth in the coming quarters. The appointment of a new statutory auditor will be a crucial step in ensuring continued financial oversight and transparency.

Risks to watch

The sequential decline in revenue needs further investigation. The company must demonstrate its ability to reverse this trend. The transition to a new statutory auditor might also introduce a temporary period of adjustment for financial reporting and audits.

Context metrics (time-bound)

For Q1 FY27 (ended June 30, 2026), Trident Texofab reported revenue of ₹26.14 crore and a net profit of ₹0.52 crore. This contrasts with Q4 FY26 (ended March 31, 2026) figures of ₹33.57 crore revenue and a net loss of ₹2.01 crore.

What to track next

Investors should closely watch the company's upcoming quarterly results to see if the profitability trend continues and if revenue can be revived. Monitoring the appointment and performance of the new statutory auditor will also be important.